Vaccines Save Lives: The Science is Clear
Decades of rigorous research, millions of lives protected, and overwhelming scientific consensus.
Explore the comprehensive evidence that demonstrates vaccine safety and effectiveness across all age groups.
Trusted by health authorities worldwide • WHO • CDC • NIH • Peer-reviewed journals
Understanding Vaccine Science
Watch how vaccines train your immune system to protect you from serious diseases
mRNA Vaccine Technology
Vaccine Development Process
Herd Immunity Explained
Comprehensive Safety Monitoring
Vaccines undergo the most rigorous testing of any medical product before approval, and safety monitoring continues throughout their use.
Pre-Approval Testing
Every vaccine undergoes extensive clinical trials involving thousands of participants across multiple phases before receiving regulatory approval.
- Phase 1: Safety testing (20-100 volunteers)
- Phase 2: Efficacy signals (hundreds)
- Phase 3: Large-scale trials (thousands to tens of thousands)
Post-Market Surveillance
Continuous monitoring systems track vaccine safety across millions of doses administered worldwide.
- VAERS (Vaccine Adverse Event Reporting System)
- Vaccine Safety Datalink (VSD)
- Clinical Immunization Safety Assessment
Independent Review
Multiple independent bodies review all vaccine data before and after approval.
- FDA’s Vaccines and Related Biological Products Advisory Committee
- CDC’s Advisory Committee on Immunization Practices
- International regulatory agencies worldwide
The Evidence: 55 Landmark Studies
Each study below has been published in prestigious peer-reviewed journals and demonstrates vaccine safety and effectiveness. Click any card to read the full research.
4-Year Mortality Study: No Long-Term Harm from mRNA Vaccines
Key Finding: No increase in long-term all-cause mortality among vaccinated individuals. In fact,
vaccinated people showed lower all-cause mortality compared to unvaccinated, with strong protection against COVID-19 death.
JAMA Network Open
Aluminum in Vaccines: No Link to Chronic Disease in 1.2 Million Children
Key Finding: No evidence of increased risk for 50 chronic health outcomes including autoimmune diseases,
allergies, autism, or ADHD associated with higher aluminum exposure from childhood vaccines.
Annals of Internal Medicine
Pfizer mRNA Vaccine: 95% Effective Against COVID-19
Key Finding: High efficacy against symptomatic COVID-19 with similar rates of serious adverse events
between vaccine and placebo groups. Expected mild-to-moderate side effects that resolve quickly.
New England Journal of Medicine
Moderna mRNA Vaccine: Proven Efficacy and Safety
Key Finding: High efficacy with acceptable safety profile and expected reactogenicity.
The trial demonstrated strong protection against symptomatic COVID-19.
American College of Physicians
Israel Study: Vaccine Effectiveness in Real World
Key Finding: Strong real-world protection against infection, hospitalization, and severe disease.
Confirmed clinical trial results translate to population-level benefits.
New England Journal of Medicine
HPV Vaccine Dramatically Reduces Cervical Cancer
Key Finding: Strong reduction in invasive cervical cancer, with greatest protection when vaccinated
at younger ages. Demonstrates real-world cancer prevention.
New England Journal of Medicine
MMR Vaccine Does Not Cause Autism: 657,461 Children Studied
Key Finding: No increased autism risk from MMR vaccine. No evidence of susceptible subgroups.
Definitively refutes the discredited autism link.
PubMed/Annals
MMR Safe Even in High-Risk Siblings
Key Finding: No increased autism risk even in children with ASD-affected siblings.
Addresses concerns about “susceptible” populations.
JAMA
Pneumococcal Vaccine Prevents Pneumonia in Adults
Key Finding: Reduced vaccine-type pneumococcal community-acquired pneumonia and invasive disease
in adults, demonstrating effectiveness beyond childhood.
JAMA Network
Rotavirus Vaccine: Strong Protection for Infants
Key Finding: Strong protection against severe rotavirus gastroenteritis with acceptable safety profile.
Prevents serious diarrheal disease in young children.
New England Journal of Medicine
Flu Vaccine in Pregnancy Protects Mom and Baby
Key Finding: Protected mothers and reduced influenza illness in infants, demonstrating
maternal immunization benefits extend to newborns.
New England Journal of Medicine
Shingles Vaccine: 97% Effective in Older Adults
Key Finding: Approximately 97% efficacy with acceptable safety. Higher reactogenicity than some vaccines,
but prevents painful and potentially debilitating shingles.
New England Journal of Medicine
One HPV Dose as Effective as Two
Key Finding: One dose of HPV vaccine non-inferior to two doses for preventing HPV16/18 infection.
Major implications for vaccine access and coverage.
New England Journal of Medicine
Hep B Vaccine Eliminates Childhood Liver Cancer
Key Finding: Marked decline in childhood hepatocellular carcinoma after universal hepatitis B vaccination.
Demonstrates vaccines can prevent cancer.
PubMed
Comprehensive Safety Study: 1.7 Million People
Key Finding: Identified rare risks like myocarditis, but these were significantly lower than risks
from COVID-19 infection itself. Overall supports vaccine safety.
New England Journal of Medicine
Comprehensive Analysis: No Link Between Vaccines and Autism
Key Finding: Comprehensive meta-analysis of multiple studies shows no association between
vaccines (MMR, thimerosal) and autism. Conclusive evidence.
PubMed
HPV Vaccine Safety: 1 Million Girls Studied
Key Finding: No increased risk of autoimmune, neurological, or thromboembolic events.
Large registry study confirms excellent safety profile.
BMJ
Pfizer Vaccine Safe and Effective for Teens
Key Finding: Very high efficacy with acceptable safety in adolescents. Important for
protecting younger age groups from COVID-19.
New England Journal of Medicine
Pfizer Vaccine for Children 5-11: Safe and Effective
Key Finding: Strong immunogenicity and efficacy with acceptable safety profile.
Age-appropriate dosing protects elementary school children.
New England Journal of Medicine
New RSV Vaccine Protects Older Adults
Key Finding: Reduced RSV-associated lower respiratory tract illness with acceptable safety.
First effective RSV vaccine for adults.
New England Journal of Medicine
Maternal RSV Vaccine Protects Newborns
Key Finding: Vaccination during pregnancy reduced severe RSV lower respiratory tract infections
in infants. Maternal immunity protects babies.
New England Journal of Medicine
HPV Vaccine Prevents Pre-Cancerous Lesions
Key Finding: Prevented HPV16/18-related high-grade cervical lesions in the per-protocol group.
Early proof of cancer prevention potential.
New England Journal of Medicine
9-Valent HPV Vaccine: Broader Protection
Key Finding: Broader type coverage (9 HPV types vs 4) with similar safety profile.
Protects against even more cancer-causing HPV strains.
PubMed
Bivalent HPV Vaccine Highly Effective
Key Finding: High efficacy against HPV16/18 persistent infection and cervical intraepithelial neoplasia.
Large international trial confirms protection.
The Lancet
Landmark MMR-Autism Study: No Association
Key Finding: No association between MMR vaccination and autism. One of the first large
population studies to definitively refute the false link.
New England Journal of Medicine
Thimerosal Does Not Harm Neurological Development
Key Finding: No consistent evidence of neuropsychological harm from early thimerosal exposure.
Addresses historical preservative concerns.
PubMed
No Autism Risk from Thimerosal Exposure
Key Finding: No increased autism spectrum disorder risk with prenatal or infant thimerosal exposure.
Further evidence against vaccine-autism link.
PubMed
PCV7 Prevents Invasive Disease in Infants
Key Finding: Prevented invasive pneumococcal disease in infants with excellent efficacy.
Landmark trial for childhood vaccination.
JAMA Network
Rotarix: Proven Protection Against Severe Gastroenteritis
Key Finding: Reduced severe rotavirus gastroenteritis with monitored safety.
Major advancement in preventing infant diarrheal disease.
PubMed
High-Dose Flu Vaccine More Effective in Seniors
Key Finding: Better efficacy in older adults compared to standard-dose vaccine.
Age-targeted formulations improve protection.
New England Journal of Medicine
Acellular Pertussis Vaccine: High Efficacy
Key Finding: High efficacy of acellular pertussis vaccine vs placebo/controls.
Modern pertussis vaccines proven safe and effective.
New England Journal of Medicine
Varicella Vaccine Prevents Chickenpox
Key Finding: Strong protection against clinical varicella with acceptable safety profile.
Prevents a once-common childhood disease.
PubMed
MenAfriVac Eliminates Meningitis Epidemics
Key Finding: Dramatic reduction in meningococcal A carriage and disease following mass vaccination campaign.
Ended devastating meningitis epidemics.
New England Journal of Medicine
Single-Dose Johnson & Johnson Vaccine Effective
Key Finding: Protective efficacy against moderate-to-severe COVID-19 with acceptable safety.
Single-dose convenience for mass vaccination.
New England Journal of Medicine
AstraZeneca Vaccine: Meaningful Protection
Key Finding: Meaningful efficacy with acceptable safety profile.
Widely used globally for COVID-19 prevention.
The Lancet
Novavax Protein Vaccine: High Efficacy
Key Finding: High efficacy in UK trial with acceptable safety.
Protein-based platform offers another effective COVID-19 vaccine option.
New England Journal of Medicine
Novavax US/Mexico Trial Confirms Efficacy
Key Finding: High efficacy with acceptable safety in large North American trial.
Consistent results across different populations.
PubMed
Pfizer Vaccine: Sustained Safety Over 6 Months
Key Finding: Efficacy maintained with consistent safety profile over 6-month follow-up period.
No new safety concerns emerged over time.
New England Journal of Medicine
Moderna Safe for Adolescents
Key Finding: Non-inferior immune response with acceptable safety in adolescents.
Moderna effective across age groups including teens.
New England Journal of Medicine
Novavax Effective in South Africa Against Variants
Key Finding: Protective efficacy demonstrated even in a variant era with acceptable safety.
Shows vaccine effectiveness against evolving strains.
New England Journal of Medicine
mRNA Booster Doses Restore Protection
Key Finding: Booster doses restore waning protection with safety profile consistent
with primary vaccination series. Important for maintaining immunity.
New England Journal of Medicine
HPV Vaccine Prevents Genital Warts and Lesions
Key Finding: Prevented HPV-related genital warts and lesions. Demonstrates broad
protection beyond cervical disease.
New England Journal of Medicine
Shingles Vaccine Highly Effective in Seniors 70+
Key Finding: High efficacy in adults 70+ years old. Reduced post-herpetic neuralgia,
a painful complication of shingles.
New England Journal of Medicine
GSK RSV Vaccine Protects Older Adults
Key Finding: Reduced RSV lower respiratory tract disease in older adults with
acceptable safety profile. Major advancement for senior health.
New England Journal of Medicine
Nirsevimab Protects Infants from RSV
Key Finding: Reduced medically attended RSV lower respiratory tract infections with
similar serious adverse events between groups. Monoclonal antibody protection.
PubMed
Nirsevimab Real-World Effectiveness Confirmed
Key Finding: Reduced RSV hospitalization and very severe disease in real-world settings.
Confirms trial results translate to practice.
PubMed
Typhoid Conjugate Vaccine Highly Protective
Key Finding: Substantial protection against culture-confirmed typhoid fever.
Important for endemic regions and global health.
New England Journal of Medicine
Hib Vaccine Eliminates Invasive Disease
Key Finding: Major reduction in invasive Haemophilus influenzae type b disease
where introduced. Nearly eliminated a leading cause of childhood meningitis.
PubMed
Polio Vaccine: Historic Breakthrough
Key Finding: Demonstrated prevention of paralytic polio. Established modern vaccine
trial methods and led to near-eradication of polio globally.
Francis Report, 1955
Measles Vaccine: High Real-World Effectiveness
Key Finding: High effectiveness demonstrated in real-world settings. Outbreaks
concentrate in undervaccinated groups, confirming vaccine protection.
PubMed
Flu Vaccine Safe During Pregnancy
Key Finding: No increased major adverse birth outcomes from influenza vaccination
during pregnancy. Supports safety for pregnant women.
PubMed
Childhood PCV Protects Adults Too
Key Finding: Indirect (herd) reductions in adult invasive pneumococcal disease after
childhood PCV introduction. Demonstrates community-wide benefits.
New England Journal of Medicine
Hepatitis A Vaccine: High Protection
Key Finding: High protection against clinical hepatitis A with good safety profile.
Prevents serious liver infection and outbreaks.
PubMed
MenC Vaccine Eliminates Disease in UK
Key Finding: Rapid decline in meningococcal C disease with herd protection.
Demonstrates both direct and indirect vaccine benefits.
PubMed
Maternal Tdap Protects Newborns from Pertussis
Key Finding: Reduced infant pertussis and hospitalization where maternal Tdap used.
Maternal antibodies protect vulnerable newborns.
PubMed
Trusted by Leading Health Organizations
Vaccines are recommended by every major medical and public health organization worldwide
WHO
World Health Organization
CDC
Centers for Disease Control
AAP
American Academy of Pediatrics
NIH
National Institutes of Health
UNICEF
United Nations Children’s Fund
FDA
Food & Drug Administration
Want to Learn More?
Explore additional resources about vaccine science, immunization schedules, and the evidence behind vaccination programs.